Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Artesunate/amodiaquine: Difference between pages

{{Short description|Malaria drug}}

| IUPAC_name = 4-oxo-4-<nowiki/>{[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0⁴,¹³.0⁸,¹³]hexadecan-10-yl]oxy}butanoic acid<ref>{{cite web | url=https://go.drugbank.com/drugs/DB09274 | title=Artesunate }}</ref>

| Verifiedfields = changed

| verifiedrevid = 477236629

<!-- Combo data -->

| type = combo

| component1 = Artesunate

| class1 = [[antimalarial drug|Antimalarial]]

| component2 = Amodiaquine

| class2 = [[antimalarial drug|Antimalarial]]

<!-- Clinical data -->

| tradename = Camoquin, others<ref name=Ai2014/>

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = C <!-- A / B / C / D / X -->

| pregnancy_category =

| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->

| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->

| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->

| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->

| legal_status =

| routes_of_administration =

<!-- Identifiers -->

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 88495-63-0

| CAS_number2 = 86-42-0

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 60W3249T9M

| UNII2_Ref = {{fdacite|correct|FDA}}

| UNII2 = 220236ED28

| ATCvet =

| ATC_prefix = P01

| ATC_suffix = BF03

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref= {{chemspidercite|correct|chemspider}}

| ChemSpiderID = none

| synonyms = ASAQ

<!-- Definition and medical uses -->

'''Artesunate/amodiaquine''', sold under the trade name '''Camoquin''' among others, is a medication used for the treatment of [[malaria]].<ref name="WHO21st" /><ref name=PMC1831475>{{cite journal | vauthors = Oyakhirome S, Pötschke M, Schwarz NG, Dörnemann J, Laengin M, Salazar CO, Lell B, Kun JF, Kremsner PG, Grobusch MP | display-authors = 6 | title = Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children | journal = Malaria Journal | volume = 6 | pages = 29 | date = March 2007 | pmid = 17352806 | pmc = 1831475 | doi = 10.1186/1475-2875-6-29 | doi-access = free }}</ref> It is a [[combination drug|fixed-dose combination]] of [[artesunate]] and [[amodiaquine]].<ref name="WHO21st" /> Specifically it recommended for acute uncomplicated ''[[Plasmodium falciparum]]'' malaria.<ref name=WHO2008>{{cite book | title = WHO Model Formulary 2008 | year = 2009 | isbn = 9789241547659 | vauthors = ((World Health Organization)) | veditors = Stuart MC, Kouimtzi M, Hill SR | hdl = 10665/44053 | author-link = World Health Organization | publisher = World Health Organization | hdl-access=free |page=187 }}</ref> It is taken by mouth.<ref name=PMC1831475/>

<!-- Side effect and mechanism -->

Common side effects include loss of appetite, [[nausea]], abdominal pain, sleepiness, trouble sleeping, and cough.<ref name=MI2010/> Safety in [[pregnancy]] is not clear; however, the medication may be used if others are not possible.<ref name=MI2010/> It is believed to be safe for use during [[breastfeeding]].<ref name=MI2010/> Artesunate and amodiaquine are both [[antimalarial medication]]; however, work by different mechanisms.<ref name=MI2010>{{cite web|title=Artesunate Amodiaquine Winthrop|url=http://www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_products/Artesunate_and_Amodiquine.pdf|website=WIPO|access-date=12 December 2016|date=August 2010|url-status=live|archive-url=https://web.archive.org/web/20161024090154/http://www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_products/Artesunate_and_Amodiquine.pdf|archive-date=24 October 2016}}</ref>

<!-- History, society and culture -->

Artesunate/amodiaquine was commercially launched in 2007.<ref name=PR2007>{{cite web|title=New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available – DNDi|url=http://www.dndi.org/2007/media-centre/press-releases/new-once-a-day-fixed-dose-combination-against-malaria-now-available/|website=www.dndi.org|access-date=12 December 2016|date=1 March 2007|url-status=live|archive-url=https://web.archive.org/web/20161220123856/http://www.dndi.org/2007/media-centre/press-releases/new-once-a-day-fixed-dose-combination-against-malaria-now-available/|archive-date=20 December 2016}}</ref> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO21st">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref> Artesunate/amodiaquine is available as a [[generic medication]].<ref name=PR2007/> As of 2014 it is not commercially available in the United States or United Kingdom.<ref name=Ai2014>{{cite book| vauthors = Ainsworth SB | chapter = Amodiaquine with artesunate |title=Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life|date=2014|publisher=John Wiley & Sons|isbn=9781118819517|page=75| chapter-url = https://books.google.com/books?id=EORvBAAAQBAJ&pg=PA75|language=en|url-status=live|archive-url=https://web.archive.org/web/20161220094547/https://books.google.ca/books?id=EORvBAAAQBAJ&pg=PA75|archive-date=2016-12-20}}</ref><ref>{{cite book| vauthors = Rosenthal PJ, Kamya M | chapter = Malaria | veditors = Goldman L, Schafer AI |title=Goldman-Cecil Medicine|date=2015|publisher=Elsevier Health Sciences|isbn=9780323322850|page=2112| chapter-url=https://books.google.com/books?id=40Z9CAAAQBAJ&pg=PA1354|language=en|url-status=live|archive-url=https://web.archive.org/web/20161220094525/https://books.google.ca/books?id=40Z9CAAAQBAJ&pg=PA1354|archive-date=2016-12-20}}</ref>

==Medical uses==

Early clinical trials showed that a once-a-day dosage was effective.<ref name="asaq dosage">{{cite journal | vauthors = Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbasoa A, Forlemu D, Moor VA, Traore A, Dicko Y, Dara N, Lameyre V, Diallo M, Djimde A, Same-Ekobo A, Gaye O | display-authors = 6 | title = Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria | journal = Malaria Journal | volume = 8 | pages = 125 | date = June 2009 | pmid = 19505304 | pmc = 2698916 | doi = 10.1186/1475-2875-8-125 | doi-access = free }}</ref> It was subsequently clinically shown to be equally effective as [[artemether/lumefantrine]],<ref name="al vs asaq">{{cite journal | vauthors = Ndiaye JL, Faye B, Gueye A, Tine R, Ndiaye D, Tchania C, Ndiaye I, Barry A, Cissé B, Lameyre V, Gaye O | display-authors = 6 | title = Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial | journal = Malaria Journal | volume = 10 | pages = 237 | date = August 2011 | pmid = 21838909 | pmc = 3171378 | doi = 10.1186/1475-2875-10-237 | doi-access = free }}</ref> although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.

==Society and culture==

Artesunate/amodiaquine was commercially launched in 2007 as an affordable treatment for malaria, devised by [[Drugs for Neglected Diseases Initiative|DNDi]] in partnership with [[Sanofi-Aventis]].<ref name=PR2007/> ASAQ was handed over to the MMV Access and Product Management Team in May 2015.<ref>{{Cite web|url=https://www.mmv.org/newsroom/news/dndi-passes-ball-mmv|title=DNDi passes the ball to MMV {{!}} Medicines for Malaria Venture|website=www.mmv.org|date=22 May 2015 |access-date=2020-02-13}}</ref>

== References ==

{{reflist}}

== External links ==

* [https://web.archive.org/web/20131212142823/http://apps.who.int/prequal/whopar/whoparproducts/MA058part3v1.pdf Patient Leaflet]

* [http://www.wipo.int/research/en/data/sanofi/marketed_products/Artesunate_and_Amodiquine.pdf Monograph (2010)] {{Webarchive|url=https://web.archive.org/web/20210827225121/https://www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_products/Artesunate_and_Amodiquine.pdf |date=2021-08-27 }}

{{Chromalveolate antiparasitics}}

{{portal bar|Medicine}}

{{DEFAULTSORT:Artesunate Amodiaquine}}

[[Category:Antimalarial agents]]

[[Category:Combination antiviral drugs]]

[[Category:Drugs developed by Pfizer]]

[[Category:World Health Organization essential medicines]]

[[Category:Wikipedia medicine articles ready to translate]]